Global testing, calibration and advisory services provider, Exova Group plc, has acquired SL Pharma Labs Incorporated (SL Pharma), a Delaware, US, based pharmaceutical business.
SL Pharma has been providing high value and high quality pharmaceutical CMC product development and quality control testing services focused primarily on parenteral, ophthalmic, intranasal and topical drug products, since 1997.
SL Pharma has a team of highly experienced pharmaceutical and biotechnology industry leaders with extensive knowledge and a commitment to providing outstanding service. Many of the company’s key people have a long history in the industry with an excellent track record of taking projects from inception through to final product approval for marketing. The business supports clients in North America, Australia, Europe and Japan to carry out product development, clinical manufacture and quality control analysis, gain regulatory approvals and meet commercial timelines and budgetary requirements, and achieved revenues of around $2.5m in 2016.
Dr. James R. Scull, Vice President, Health Sciences Americas, said: “This acquisition significantly enhances our technical expertise and service offering within the pharmaceutical market and complements our existing testing facilities in North America. The addition of SL Pharma to our portfolio is a clear demonstration of our commitment to developing our pharmaceutical business by expanding our testing capabilities to meet CMC product development and the rapidly growing need for Phase I and II clinical supplies manufacture.”
Waheed Sheikh, President, SL Pharma, said: “Becoming part of a global testing and advisory business is a great move for SL Pharma, our team and our customers as it gives us access to new capabilities and expertise. I look forward to working with Exova to continue to grow the business and take the SL Pharma name and reputation to exceptional new levels.”